Head and Neck Squamous Cell Carcinoma Cell Line-Induced Suppression of in vitro Lymphocyte Proliferative Responses

1992 ◽  
Vol 106 (2) ◽  
pp. 149-158 ◽  
Author(s):  
Henry Lapointe ◽  
Howard Lampe ◽  
Diponkar Banerjee

Tumour-infiltrating lymphocytes (TILS) are often difficult to expand in vitro. In some cases this has been attributable to immunosuppression mediated by the elaboration of prostaglandins by either tumor cells or tumor-infiltrating monocytes. In this laboratory, freshly prepared TILs containing single-cell suspensions of head and neck tumors displayed both poor proliferation as well as minimal responsiveness to indomethacin-mediated reversal of immunosuppression. In order to investigate tumor-mediated immunosuppression further, a system was developed whereby a new cell line of head and neck squamous cell carcinoma was used to suppress allogeneic peripheral blood mononuclear cell proliferation in response to phytohemagglutinin (PHA) and interieukin-2 (IL-2). Tumor cells were able to suppress peripheral blood mononuclear cell (PBMNC) proliferation up to 95%. This suppressive effect was dependent on tumor cell number and was reversible by the use of higher concentrations of PHA, but not by increased concentrations of IL-2. Suppression was immediate when IL-2 was used as the stimulus for proliferation, but required extended lymphocyte/tumor cell contact when PHA was used. Flow cytometric analysis of tumor-exposed and PHA-stimulated PBMNCs revealed a decrease in both the number of cells expressing IL-2 receptors as well as the density of IL-2 receptors per cell. This pattern of suppression, as well as the reversibility of suppression by indomethacin, implicates prostaglandins in the mechanisms by which these tumor cells mediate immunosuppression.

Oral Diseases ◽  
2018 ◽  
Vol 25 (1) ◽  
pp. 64-72 ◽  
Author(s):  
Areeya Arayataweegool ◽  
Ratakorn Srisuttee ◽  
Patnarin Mahattanasakul ◽  
Napadon Tangjaturonsasme ◽  
Virachai Kerekhanjanarong ◽  
...  

Oral Diseases ◽  
2020 ◽  
Author(s):  
Fardeela Bin‐Alee ◽  
Areeya Arayataweegool ◽  
Supranee Buranapraditkun ◽  
Patnarin Mahattanasakul ◽  
Napadon Tangjaturonrasme ◽  
...  

2009 ◽  
Vol 141 (2) ◽  
pp. 177-183 ◽  
Author(s):  
Mindy R. Figures ◽  
Jessie Wobb ◽  
Koji Araki ◽  
Tingyan Liu ◽  
Lei Xu ◽  
...  

OBJECTIVE: The current treatment for advanced head and neck squamous cell carcinoma continues to result in poor outcomes. The purpose of this study is to investigate the benefit of fibroblast growth factor 2-targeted adenovirus-mediated mutant-Rad50 (FGF2-Ad-Rad50) gene transfer in enhancing chemosensitization for head and neck squamous cell carcinoma and reducing chemotoxicity. STUDY DESIGN: Randomized controlled laboratory study. SETTING: University of Pennsylvania, Philadelphia, PA. SUBJECTS AND METHODS: Human head and neck squamous cell carcinoma tumor cells and a mouse model with human head and neck squamous cell carcinoma were used for this study. There were five mice in each study group. FGF2-fab' molecule was conjugated with an adenoviral mutant-Rad50 construct. FGF2-targeted transgene expression efficiency was evaluated in vitro. Tumor cytotoxicity and growth inhibition were examined after combined FGF2-Ad-Rad50 with cisplatin treatment in vitro and in vivo. Anti-tumor mechanisms were investigated. RESULTS: FGF2-targeted gene transfer approach significantly improved transgene expression in head and neck squamous cell carcinoma tumor cells over a nontargeted approach (207.51 ± 33.62 vs 51.44 ± 8.28, respectively). FGF2-Ad-Rad50 with cisplatin demonstrated a superior tumor suppression effect (264.5 ± 124.1 mm 3 vs 567.1 ± 267.6 mm 3 ), increased DNA double-strand breaks (1349 ± 51.67 vs 774 ± 28.56), and anti-angiogenesis (%ROI: 0.76% ± 0.38% vs 2.10% ± 1.66%) in tumor cells over nontargeted adenovirus. CONCLUSION: Combination of FGF2-Ad-Rad50 with cisplatin significantly improves anti-tumor effect by targeting DNA repair systems and tumor angiogenesis. The great benefit of this strategy supports clinical trial for novel treatment of head and neck squamous cell carcinoma.


Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2751
Author(s):  
Kariem Sharaf ◽  
Tanja K. Eggersmann ◽  
Stefan P. Haider ◽  
Sabina Schwenk-Zieger ◽  
Jiefu Zhou ◽  
...  

Human adipose-derived stem/stromal cells (ASCs) are increasingly used as auto-transplants in regenerative medicine to restore tissue defects or induce wound healing, especially in cancer patients. The impact of ASCs on squamous cell carcinoma of the upper aerodigestive tract (UAT) including head and neck and esophageal squamous cell carcinoma (HNSCC and ESCC) is not yet fully understood. ASCs were cultured from subcutaneous, abdominal lipoaspirates of five patients, who received auto-transplants to the head and neck. Supernatants were tested for paracrine effects in functional in vitro assays of proliferation of HNSCC tumor cell line FaDu and ESCC cell line Kyse30, and their cell migration/invasion capacities in Boyden chambers, in addition to endothelial tube formation assay using human umbilical vein endothelial cells (HUVECs). All ASC-derived supernatants enhanced proliferation of FaDu cells, invasive migration, and tube formation by HUVECs, compared to controls. Of five patients’ lipoaspirates, ASC-derived supernatants of four patients increased proliferation and invasive migration in Kyse30 cells. The data suggests that ASCs can promote tumor cell proliferation, invasiveness, and neo-angiogenesis in these tumor cell lines of the UAT and HUVEC in a paracrine manner. Although clinical studies on the subject of oncological safety are still needed, these findings emphasize the importance of complete tumor removal before ASCs are used in the head and neck.


2020 ◽  
Vol 8 (Suppl 2) ◽  
pp. A46.1-A46
Author(s):  
AS Köseer ◽  
C Arndt ◽  
A Feldmann ◽  
A Linge ◽  
M Krause ◽  
...  

BackgroundMost patients with head and neck squamous cell carcinomas (HNSCC) are diagnosed during a locally advanced stage and may show therapy resistance. Retrospectively, we showed that low CD98hc mRNA and protein levels are significantly associated with better locoregional tumor control in HNSCC patients.1,2 Inhibition of CD98hc expression decreased tumor radioresistance suggesting that CD98hc could be a target for HNSCC radiosensitization. One of the strategies for radiosensitization is targeted immunotherapy. However, Chimeric Antigen Receptor (CAR)-equipped T-cell therapy cannot be fully controlled. Therefore, we developed a switchable UniCAR system that is in phase I clinical trial (NCT04230265) [3]. UniCAR T cell activity and specificity are controlled by the presence of target modules (TM) with short half-lives.3 We aim to define the clinical value of treatment approaches by combining radio(chemo)therapy with CD98hc-targeted immunotherapy.Materials and MethodsWe have used previously described radioresistant Cal33 HNSCC cells.2 These tumor cells were cocultured with UniCAR T cells in the presence or absence of a novel CD98 TM. Specific cell lysis in both in vitro 2D and 3D cultures and tumor cell targeting in the experimental mice was assessed.4ResultsOur data shows that CD98-redirected UniCAR T cells can induce cell lysis of radioresistant HNSCC cells in vitro and in vivo models. The combination of the UniCAR system with radio(chemo)therapy can be potentially used for the improvement of the treatment efficacy in patients with metastatic radioresistant tumors. The most promising combination of therapeutic approaches will be further tested in xenograft tumor models to evaluate the best performing combination of immunotherapy and radio(chemo)therapy.ConclusionsOverall, it was shown that tumor cells with radioresistant properties can be eradicated via the UniCAR system by targeting CD98hc in an antigen-specific manner.ReferencesLinge A, et al., Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clin Cancer Res 2016. 22(11): 2639–49.Digomann D, et al., The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clin Cancer Res 2019. 25(10): 3152–63.Bachmann M, et al., The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett 2019;211:13–22.Arndt C, et al., UniCAR T Cell Immunotherapy Enables Efficient Elimination of Radioresistant Cancer Cells. Oncoimmunology 2020.9(1): 1743036.Disclosure InformationA.S. Köseer: None. C. Arndt: None. A. Feldmann: None. A. Linge: None. M. Krause: None. A. Dubrovska: None. M. Bachmann: E. Ownership Interest (stock, stock options, patent or other intellectual property); Significant; GEMoaB.


Sign in / Sign up

Export Citation Format

Share Document